https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Monitoring patient response to pembrolizumab with peripheral blood exhaustion marker profiles https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44986 Wed 26 Oct 2022 15:06:56 AEDT ]]> Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30091 Wed 11 Apr 2018 12:04:08 AEST ]]> Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46496 Thu 24 Nov 2022 12:14:09 AEDT ]]> Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34826 Thu 13 Jan 2022 10:31:11 AEDT ]]> Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29413 Sat 24 Mar 2018 07:36:21 AEDT ]]> Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29414 Sat 24 Mar 2018 07:36:12 AEDT ]]> Association of pembrolizumab with tumor response and survival among patients with advanced melanoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29369 Sat 24 Mar 2018 07:34:17 AEDT ]]>